Anne Borgman
Chief Tech/Sci/R&D Officer bei SUTRO BIOPHARMA, INC.
Vermögen: 137 713 $ am 31.03.2024
Profil
Anne E Borgman is currently a Director at Curis, Inc. She also holds current positions as an Independent Director at NextCure, Inc., Director at NiKang Therapeutics, Inc., and Chief Medical Officer at Sutro Biopharma, Inc. In the past, she worked as Head-Global Project at Abbott Laboratories, Vice President-Clinical Research & Development at Exelixis, Inc., and Vice President & Head-Global Therapeutic Area at Jazz Pharmaceuticals Plc.
She also served as Clinical Associate-Pediatrics at The University of Chicago and held positions as Chief Medical Officer & Vice President at both Humanigen, Inc. and Talon Therapeutics, Inc. Additionally, she was an Associate Chief Medical Officer at Kalobios Pharmaceuticals, Inc. Dr. Borgman received her undergraduate degree from the University of Illinois and her doctorate from Stritch School of Medicine.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
SUTRO BIOPHARMA, INC.
0,04% | 05.03.2024 | 24 374 ( 0,04% ) | 137 713 $ | 31.03.2024 |
NEXTCURE, INC.
-.--% | 22.06.2023 | 0 ( -.--% ) | - $ | 31.03.2024 |
CURIS, INC.
-.--% | 25.03.2024 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Anne Borgman
Unternehmen | Position | Beginn |
---|---|---|
NEXTCURE, INC. | Director/Board Member | 01.10.2021 |
CURIS, INC. | Director/Board Member | - |
SUTRO BIOPHARMA, INC. | Chief Tech/Sci/R&D Officer | 28.02.2023 |
NiKang Therapeutics, Inc.
NiKang Therapeutics, Inc. BiotechnologyHealth Technology NiKang Therapeutics, Inc. operates as biotechnology company. It focuses on developing novel small molecule oncology drug discovery. The company was founded by Zhenhai Gao and is headquartered in Wilmington, DE. | Director/Board Member | 18.01.2023 |
Ehemalige bekannte Positionen von Anne Borgman
Unternehmen | Position | Ende |
---|---|---|
JAZZ PHARMACEUTICALS PLC | Corporate Officer/Principal | 01.03.2022 |
EXELIXIS, INC. | Corporate Officer/Principal | 01.07.2019 |
The University of Chicago | Corporate Officer/Principal | 01.01.2010 |
ABBOTT LABORATORIES | Corporate Officer/Principal | 01.11.2007 |
Kalobios Pharmaceuticals, Inc. | Corporate Officer/Principal | - |
Ausbildung von Anne Borgman
University of Illinois | Undergraduate Degree |
Stritch School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 7 |
---|---|
ABBOTT LABORATORIES | Health Technology |
EXELIXIS, INC. | Health Technology |
CURIS, INC. | Health Technology |
HUMANIGEN, INC. | Health Technology |
SUTRO BIOPHARMA, INC. | Health Technology |
JAZZ PHARMACEUTICALS PLC | Health Technology |
NEXTCURE, INC. | Health Technology |
Private Unternehmen | 3 |
---|---|
Talon Therapeutics, Inc.
Talon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Talon Therapeutics, Inc. is a biopharmaceutical company, which is engaged in the developing and commercializing new and differentiated cancer therapies. The firm is developing the Marqibo for the treatment of acute lymphoblastic leukemia and other blood cancers including lymphoma. Its Menadione topical lotion is a compound which is developed for the prevention and treatment of skin toxicity associated with epidermal growth factor receptor inhibitors. The company was founded by Mark J. Ahn in 2002 and is headquartered in San Mateo, CA. | Health Technology |
NiKang Therapeutics, Inc.
NiKang Therapeutics, Inc. BiotechnologyHealth Technology NiKang Therapeutics, Inc. operates as biotechnology company. It focuses on developing novel small molecule oncology drug discovery. The company was founded by Zhenhai Gao and is headquartered in Wilmington, DE. | Health Technology |
Kalobios Pharmaceuticals, Inc. |